









Markets
/
Stocks
/
nasdaq-cntx
/

Context Therapeutics Inc

CNTX

0.968USD

-0.032-3.18%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

86.85MMarket Cap

LossP/E TTM



Context Therapeutics Inc

0.968

-0.032-3.18%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

207 / 506

Overall Ranking

332 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 7 analysts

Buy

Current Rating

5.167

Target Price

+416.67%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Context Therapeutics Inc. is a biopharmaceutical company advancing medicines for solid tumors. The Company is building an advanced portfolio of clinical-stage T cell engaging bispecific therapeutics, including CTIM-76, a selective Claudin 6 (CLDN6) x CD3 bispecific antibody, and CT-95, a potential first-in-class mesothelin x CD3 bispecific antibody. CLDN6 is a tight junction membrane protein target expressed in multiple solid tumors, including ovarian, endometrial, testicular, and lung, and absent from or expressed at low levels in healthy adult tissues. CTIM-76 is capable of binding to tumor cells expressing CLDN6 and stimulating intra-tumoral T cells by the CD3 arm that is designed to be activated only upon tumor engagement while silent elsewhere. CTIM-76 has the potential for a wide therapeutic window. The Company’s CT-95 is being developed as a therapy for advanced cancers associated with mesothelin (MSLN) expression.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 80.14.

Fairly Valued

The company’s latest PE is -2.24, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 72.82M shares, decreasing 8.03% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 3.36M shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.93.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -2.32, which is -15.92% below the recent high of -1.95 and -4.76% above the recent low of -2.43.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 207/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.33, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Context Therapeutics Inc is 4.50, with a high of 9.00 and a low of 4.00.

Score

Industry at a Glance

Previous score

8.33

Change

Support & Resistance

No Data

Analyst Rating

Based on 7 analysts

Buy

Current Rating

5.167

Target Price

+433.64%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Context Therapeutics Inc

CNTX

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 9.07, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 1.07 and the support level at 0.87, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.07

Change

-0.45

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.021

Buy

RSI(14)

67.762

Neutral

STOCH(KDJ)(9,3,3)

69.307

Neutral

ATR(14)

0.056

Low Volatility

CCI(14)

267.222

Overbought

Williams %R

39.154

Buy

TRIX(12,20)

0.386

Sell

StochRSI(14)

75.262

Sell

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

0.901

Buy

MA10

0.869

Buy

MA20

0.860

Buy

MA50

0.814

Buy

MA100

0.748

Buy

MA200

0.847

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 81.17%, representing a quarter-over-quarter increase of 0.03%. The largest institutional shareholder is The Vanguard, holding a total of 3.36M shares, representing 3.75% of shares outstanding, with 13.69% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

MPM BioImpact LLC

14.71M

Avidity Partners Management LP

7.48M

Nextech Invest, Ltd.

7.42M

Deep Track Capital LP

7.42M

Blue Owl Capital Holdings LP

7.37M

+15.89%

Great Point Partners, LLC

4.68M

Franklin Advisers, Inc.

4.00M

The Vanguard Group, Inc.

Star Investors

3.25M

-0.06%

Blackstone Alternative Asset Management, L.P.

2.44M

Nantahala Capital Management, LLC

1.94M

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.05, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 1.91. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.